Citius Pharmaceuticals Inc (CTXR) Stock Price, Quote & News

Company Profile

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic reli...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 967 6677

Website: citiuspharma.com

Address:

11 Commerce Drive, First Floor, Cranford, United States

np_stocks Mar. 21 at 1:24 AM

$CTXR all the fraud, lies, manipulation . - Thank you management you guys rock!

0 · Reply

Applebat Mar. 20 at 8:19 PM

$CTXR First they pump it Then they dump it

0 · Reply

donein12 Mar. 19 at 11:29 AM

$CTXR Kinda says it all: Because we are not a commercial-stage company, we did not have any revenue during the periods presented. Consequently, our company has not historically looked to net income (loss) as a performance measure for our executive compensation program. In 2023 and 2024, our net loss increased, with our net loss decreasing between 2024 and 2025, whereas the compensation actually paid for both our PEO increased between 2024 and 2025. The compensation actually paid to our PEO and the average amount of compensation actually paid to our Non-PEO NEOs during the periods presented are not directly correlated with TSR. WOW!! See pages 24,26,27 on below link: https://www.otcmarkets.com/filing/html?id=19176454&guid=nKx-keKroL_cwch

0 · Reply

SweStonk Mar. 18 at 6:20 PM

$CTXR well well, lymphir seem not to have been what u all expected. $CTOR sinking faster than titanic. ML = dead Halo = dead Lymphir was the last shot and sales are nowhere near what is needed. Dilution anyday to slow the sinking, but it is invetable at this point. Using shareholders money to buy lymphir and put the company in great debt was the most stupid thing management could do. Bankruptcy incoming and deerfield will scoop this up cheap and take it private. Shareholders get nothing.

0 · Reply

SweStonk Mar. 17 at 5:30 PM

$CTXR no bottom in sight! Nothing to hold this up. Dilution anyday

1 · Reply

900fix Mar. 17 at 11:43 AM

$CTXR Fire Lenny. The only last hope CTXR has.

0 · Reply

Cruiser24 Mar. 16 at 4:04 PM

$CTXR BULLISH CONTINUING "—which can sometimes mean a second, smaller trial—if a single trial's data is viewed as insufficient.Trial Design & Controls:Mino-Lok's Phase 3 was an open-label study (though assessor-blinded), comparing it to a "clinician-directed" control arm.The FDA sometimes scrutinizes the lack of a standardized control arm or the open-label nature, which can lead to requests for more data to confirm the "superiority" claim.Regulatory Alignment:In a November 2024 Type C meeting, the FDA provided "actionable guidance" for the NDA.This feedback often includes "remaining steps" like additional safety data or CMC (Chemistry, Manufacturing, and Controls) information that must be resolved before a final decision. GOID LUCK BULLS 🍀💎✋🤚💎💎✋🤚💎🍀

0 · Reply

Cruiser24 Mar. 16 at 3:51 PM

$CTXR BULLISH The FDA has not officially required an entirely new clinical trial for Mino-Lok (MLT) following its Phase 3 success. However, several regulatory hurdles often lead to requests for additional data or supplemental studies during the NDA submission process:Catheter Compatibility Requirements:The FDA previously required catheter compatibility studies to ensure Mino-Lok does not degrade various types of central venous catheters (CVCs) or peripherally inserted central catheters (PICCs).These are technical, in-vitro studies rather than large-scale patient trials, but they are essential for broad labeling.Need for "Confirmatory Evidence":Historically, the FDA has required two independent pivotal studies to prove a drug's efficacy is not a statistical fluke.While new 2026 guidance suggests the FDA may move away from the strict two-trial standard, they still often require "confirmatory evidence"—. TO BE CONTINUED GOOD LUCK. BULLS 🍀💎✋🤚💎💎✋🤚💎🍀

1 · Reply

900fix Mar. 16 at 3:02 PM

$CTXR Phase 1 test will not save CTXR. Years away. Lenny drove this into the dirt with Mino-Lok he knew would never be approved. Everyone will pick through the bones of this mis-managed scam if they see something of value when Lenny sucks the last dollar out of it.

0 · Reply

Idkwhattonamemyself Mar. 16 at 8:55 AM

$CTXR The worst investment on the stock market.

0 · Reply

Market Cap	18.47M
Revenue (ttm)	0.00
Net Income (ttm)	-37.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	393,500
Avg Vol	568,424
Day's Range	N/A - N/A
Shares Out	22.38M
Stochastic %K	7%
Beta	1.51
Analysts	Sell
Price Target	$6.00